Definium Therapeutics (DFTX) Enterprise Value (2020 - 2026)

Definium Therapeutics (DFTX) has reported Enterprise Value for 5 consecutive years, with -$368.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Enterprise Value fell 73.27% year-over-year to -$368.1 million; the TTM figure through Mar 2026 stood at -$368.1 million (down 73.27% YoY), while the FY2025 annual figure was -$409.1 million, down 50.68% from the prior year.
• Enterprise Value advanced to -$368.1 million in Q1 2026 per DFTX's latest filing, from -$409.1 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$96.7 million in Q4 2023 and bottomed at -$409.1 million in Q4 2025.
• Historically, Enterprise Value has averaged -$204.6 million across 5 years, with a median of -$194.3 million in 2025.
• Annual changes were most pronounced in 2024 — Enterprise Value slumped 180.77% — and 2025, when it grew 29.2%.
• Definium Therapeutics' Enterprise Value stood at -$131.7 million in 2022, then gained by 26.58% to -$96.7 million in 2023, then plunged by 180.77% to -$271.5 million in 2024, then sank by 50.68% to -$409.1 million in 2025, then rose by 10.02% to -$368.1 million in 2026.
• Business Quant data shows DFTX's Enterprise Value at -$368.1 million in Q1 2026, -$409.1 million in Q4 2025, and -$209.1 million in Q3 2025.